Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments
|ClinicalTrials.gov Identifier: NCT01642706|
Recruitment Status : Unknown
Verified November 2015 by University Hospital, Montpellier.
Recruitment status was: Recruiting
First Posted : July 17, 2012
Last Update Posted : November 20, 2015
|Condition or disease|
|Rheumatoid Arthritis Osteoarthritis Systemic Lupus Erythematosus Sjogren's Syndrome Scleroderma Spondylitis Gout Spinal Disease Chondrocalcinosis|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Observational Model:||Case Control|
|Official Title:||Regulatory B Cells in Inflammatory Rheumatisms, Systemic Auto-immune Diseases in Adults and Biomarkers of Response to Biologic Treatments|
|Study Start Date :||July 2012|
|Estimated Primary Completion Date :||July 2016|
|Estimated Study Completion Date :||July 2016|
Patients affected by Rheumatoid arthritis.
Subjects affected by mechanical pathologies.
- Assessment of Bregs levels [ Time Frame: 30 months ]The levels of Bregs will be assessed in patients with RA and compared to subjects with mechanical pathologies.
- Change of Bregs levels after therapy [ Time Frame: 30 months ]The levels of Bregs will be assessed in patients who will start a therapy within the framework of their usual follow-up.
Biospecimen Retention: Samples Without DNA
Comparison of Bregs levels
Lymphocytes will be analyzed from :
- circulating blood
- articular serum
- synovial membrane
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01642706
|Contact: Jacques Morel, MD, PhDemail@example.com|
|Contact: Claire Daien, MDfirstname.lastname@example.org|
|Montpellier, France, 34295|
|Contact: Jacques Morel, MD, PhD 0033467338710 email@example.com|
|Contact: Claire Daien, MD 0033673042406 firstname.lastname@example.org|
|Principal Investigator: Jacques Morel, MD, PhD|
|Principal Investigator:||Jacques Morel, MD, PhD||University Hospital, Montpellier|